Structure of CC-90011

selective, reversible LSD1 inhibitor

<100 mg orally QW, in Ph. II for 1L ES-SCLC

from 300k+ cmpd HTS, SBDD + opt.

J. Med. Chem., Oct. 9, 2020

Celgene/Bristol Myers Squibb, San Diego, CA

CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.